Systems and processes for distinguishing pathogenic and non-pathogenic sequences from specimens

US12305231B2 · kind B2 · utility

Assignee

• Clear Labs, Inc · US

Inventors

• Sasan Amini · Redwood City, US
• Ramin Khaksar · Redwood City, US
• Michael Taylor · San Mateo, US
• Prasanna Thwar Krishnan · San Jose, US
• David Tran · Edmonton, CA
• Shaokang Zhang · Union City, US
• Shadi Shokralla · Danville, US
• Kyle Rhoden · Omaha, US
• Susan Jisoon Lee · South San Francisco, US
• Bryan Thomas Barney · San Jose, US
• Sima Mortazavi · Foster City, US
• Adam ALLRED · Menlo Park, US
• Henrik Gehrmann · Newark, US

Key dates

• Filing date: Nov 19, 2021
• Grant date: May 20, 2025
• Expiry date: Mar 21, 2044

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2563/185
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Provided herein are fully-automated next-generation sequencing platforms and processes for detection of a target specimen (e.g., SARS-CoV-2) and for distinguishing infectious from non-infectious signals from the specimen. An analysis can provide simultaneous diagnosis and genomic surveillance of a multitude of distinct specimens in a sample information. The analysis can comprise distinguishing between infectious versus infectious specimens and provide a recommendation as to how infectious the sample can be. The information on can be used to better inform the status of a subject or a location with regards to infectivity from the specimen.